PARP inhibitors as maintenance treatment for pancreatic cancer patients with germline BRCA mutations

被引：0
|
作者：
Kawecki, Maciej [1 ]
机构：
[1] Maria Sklodowska Curie Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 03期
关键词：
D O I：
10.5603/OCP.2019.0023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：190 / 193
页数：4
相关论文
共 50 条
  • [41] PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies
    Bahena-Gonzalez, Antonio
    Toledo-Leyva, Alfredo
    Gallardo-Rincon, Dolores
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [42] PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
    Shao, Fengping
    Duan, Yaoyun
    Zhao, Yunhe
    Li, Yinguang
    Liu, Jun
    Zhang, Cai
    He, Shanyang
    AGING-US, 2021, 13 (06): : 8975 - 8988
  • [43] PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations
    Layman, Rachel M.
    Arun, Banu
    CANCER JOURNAL, 2021, 27 (01): : 67 - 75
  • [44] Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
    Ashour, Mohamed
    Shafik, Hanan Ezzat
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6275 - 6284
  • [45] POLO: Patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Kindler, H.
    Yoo, H.
    McGuinness, D.
    Cui, K.
    Joo, S.
    Locker, G.
    Golan, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S134 - S134
  • [46] Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
    Sandhu, S. K.
    Omlin, A.
    Hylands, L.
    Miranda, S.
    Barber, L. J.
    Riisnaes, R.
    Reid, A. H.
    Attard, G.
    Chen, L.
    Kozarewa, I.
    Gevensleben, H.
    Campbell, J.
    Fenwick, K.
    Assiotis, I.
    Olmos, D.
    Yap, T. A.
    Fong, P.
    Tunariu, N.
    Koh, D.
    Molife, L. R.
    Kaye, S.
    Lord, C. J.
    Ashworth, A.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2013, 24 (05) : 1416 - 1418
  • [47] POLO: patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Arnold, D.
    Yoo, Kyoo H.
    Kindler, H. L.
    McGuinness, D.
    Cui, K. Y.
    Joo, S.
    Golan, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 224 - 224
  • [48] PARP Inhibitors in Breast Cancer: BRCA and Beyond
    Rios, Jorge
    Puhalla, Shannon
    ONCOLOGY-NEW YORK, 2011, 25 (11): : 1014 - 1025
  • [49] PARP inhibitors in cancer: moving beyond BRCA
    Telli, Melinda L.
    LANCET ONCOLOGY, 2011, 12 (09): : 827 - 828
  • [50] Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy
    P. Ghiorzo
    V. Pensotti
    G. Fornarini
    S. Sciallero
    L. Battistuzzi
    F. Belli
    L. Bonelli
    G. Borgonovo
    W. Bruno
    A. Gozza
    S. Gargiulo
    L. Mastracci
    S. Nasti
    G. Palmieri
    F. Papadia
    L. Pastorino
    A. Russo
    V. Savarino
    L. Varesco
    L. Bernard
    G. Bianchi Scarrà
    Familial Cancer, 2012, 11 : 41 - 47
12345